Roivant Sciences - Funding, Financials, Valuation, Investors - Cointime

比特币 ¥600,965.12 -0.34%
以太坊 ¥14,211.70 +0.69%
币安币 ¥4,479.55 -1.41%
Optimism ¥6.18 +1.05%
Arbitrum ¥2.63 +1.09%
Solana ¥919.81 -0.48%
Polygon ¥1.50 +1.18%
Cosmos ¥35.27 +6.71%
Avalanche ¥139.70 +1.57%

比特币 ¥600,965.12 -0.34%
以太坊 ¥14,211.70 +0.69%
币安币 ¥4,479.55 -1.41%
Optimism ¥6.18 +1.05%
Arbitrum ¥2.63 +1.09%
Solana ¥919.81 -0.48%
Polygon ¥1.50 +1.18%
Cosmos ¥35.27 +6.71%
Avalanche ¥139.70 +1.57%

Roivant Sciences

company

Investors

Number of Lead Investors

Number of Investors

5

15

Roivant Sciences is funded by 15 investors. Novaquest Capital Management and Dainippon Sumitomo Pharma are the most recent investors.

Investor Name	Lead Investor	Funding Round
Novaquest Capital Management	Yes	Private Equity（PE）
Dainippon Sumitomo Pharma	-	Post-IPO Equity
Eventide	-	Post-IPO Equity
Fidelity Management and Research Company	-	Post-IPO Equity
Palantir Technologies	-	Post-IPO Equity
Patient Square Capital	-	Post-IPO Equity
RTW Investments	-	Post-IPO Equity
SoftBank Capital	-	Post-IPO Equity
Suvretta Capital Management	-	Post-IPO Equity
Viking Global Investors	-	Post-IPO Equity
Dexcel Pharma	-	Private Equity（PE）
Founders Fund	-	Private Equity（PE）
QVT Financial	-	Private Equity（PE）
SoftBank Vision Fund	-	Private Equity（PE）
Sahsen Ventures	-	Private Equity（PE）